Sai Parenterals' monitoring agency flags ₹23.87 Cr of IPO-proceeds deviations the company reported as nil

Sai Parenterals raised a ₹2,850 million (₹285 crore) fresh issue at ₹392 per share in its March 2026 IPO — part of a ₹4,087.89 million (₹408.79 crore) total issue that included a ₹1,237.89 million (₹123.79 crore) offer for sale. On October 3, the company filed the Monitoring Agency Report of India Ratings & Research for the quarter ended June 30, 2026 — the agency appointed under its February 12, 2026 monitoring agreement to track how those proceeds are spent. The report's opening answer to "Deviation from the objects" is Yes: deviations amounting to ₹238.74 million, i.e. ₹23.87 crore — about 8.4% of the fresh issue by our arithmetic, within the "up to 10%" range the agency states. What makes the report notable is not just the number but the contrast with the company's own disclosure two months earlier.

The largest single item is Note 3. The company moved ₹189.91 million (₹18.99 crore) from the monitoring account toward general corporate purposes; of that, ₹149.21 million (₹14.92 crore) was routed through common operating accounts where issue proceeds sat alongside ordinary business funds. The agency's conclusion, in its own words: it "could not independently ascertain the end utilization" of that amount. Its break-up of the ₹149.21 million: ₹44.15 million related to transactions executed after June 30, ₹58.90 million was mapped to bank accounts that had never received issue proceeds (so the "nexus with issue proceeds could not be independently established"), and ₹46.16 million was not utilized on the day of transfer. The company did provide identified utilization entries for the full amount — statutory taxes (₹72.87 million), salaries and wages including director remuneration (₹65.92 million), raw-material vendor payments (₹49.46 million) and business development (₹1.67 million) — but identification by the company is not the same as independent verification by the agency.

The BRLM item deserves unpacking. The company paid ₹100 million (₹10 crore) in aggregate from the escrow account to Arihant Capital Markets Limited, the book-running lead manager — ₹69.72 million against the fresh-issue portion and ₹30.28 million against the offer-for-sale portion. The agency treated it as a deviation because the payment "is not supported by invoices/ agreement." The company has represented, supported by email confirmations, that the amount was a refundable security deposit towards IPO-related expenses and was refunded after the reporting period. Note the arithmetic: the four note amounts plus the ₹69.72 million fresh-issue portion of this payment sum to exactly ₹238.74 million — which suggests the agency counted only the fresh-issue share of the BRLM payment against the deviation total. A ₹10 crore payment to a lead manager resting on email confirmations rather than invoices, even if since refunded, is the kind of item the next quarterly report will need to show as closed.

Three things stand out in the table. First, issue-related expenses ran to ₹321.35 million against the ₹284.99 million provided in the prospectus — an overshoot of ₹36.36 million that the report shows as a negative unutilized balance. Second, the two build-out objects have barely started: only ₹68.05 million of the ₹1,107.95 million capacity-expansion allocation was spent (and that figure itself includes ₹1.54 million paid to a vendor other than those specifically disclosed in the prospectus), and the R&D centre has seen no deployment at all. The prospectus expected infrastructure work and plant-and-machinery orders for Units II and III to be completed by June 2026; the report records this as in progress, with board-approved timeline extensions to December 2026 for Unit III and January 2027 for Unit IV, and the Unit I and II utilization objects revised with approvals on September 10, 2026. Third, the unspent ₹1,447.73 million (₹144.77 crore) — just over half the fresh issue — is parked: ₹1,450 million across fixed deposits with Axis Bank and CUB at 6.90–7.30%, plus small balances in the monitoring and escrow accounts, totalling ₹1,464.34 million including ₹16.61 million of interest earned on matured deposits.

The board's defence, recorded in the report itself, is consistent across the notes: the money reached its intended objects, and "the timing difference in physical utilization does not negate the allocation and deployment of funds toward the specified purpose." On the interest payment, the board argues the ₹1.28 million was an integral part of completing the repayment objective, and that total utilization of ₹136.54 million stayed within the ₹143.02 million allocated. Those are substantive arguments — this is a dispute about monitoring discipline and documentation, not an allegation of missing money. But the agency's counterpoints are procedural facts, not opinions: funds left the monitoring account before they were spent, a material payment lacked invoices, and the shareholder approval the agency says material deviations require was not obtained. Separately, the compliance chair changed in the same window: Company Secretary and Compliance Officer Shivali Aggarwal's resignation — first intimated on August 11 as effective on or before October 12 — was approved effective September 30, with Ashwani Singh Bisht appointed Company Secretary and Arvind appointed COO the same day. The filings record no connection between the two threads.

The stock has drifted from its 52-week high of ₹705 on July 2 to a 52-week low of ₹491.65 on September 16, closing at ₹522.80 on October 1 — down 25.8% from the high but still 33.4% above the ₹392 IPO price. The session after the August 11 evening filings (Q1 results plus the "no deviations" statement) closed −3.7%, though the two filings cannot be separated in that move. The Monitoring Agency Report reached the exchange on Saturday, October 3; its first tradable session falls outside the price data in this report, so how the market weighs ₹23.87 crore of flagged deviations against a company that is otherwise growing — Q1 FY27 consolidated revenue of ₹178.7 crore against ₹33.4 crore a year earlier, per the company's press release — remains the open question.